Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Dr. Lal Path Labs announced strong Q1 FY27 consolidated financial results, with revenue growing 19.1% to Rs.798 cr and net profit increasing 27.2% to Rs.170 cr. The company also declared an interim dividend of Rs.5 per share.
Jul 24 2026 14:17:40
Dr. Lal PathLabs Ltd - 539524 - Corporate Action-Board approves Dividend
Dr. Lal Path Labs declared an interim dividend of ₹5 per equity share for FY27. The record date for this dividend is July 30, 2026, with payment due within 30 days.
Jul 24 2026 13:57:05
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Acquisition
Dr. Lal Path Labs' subsidiaries acquired stakes in two companies: 80% in Ghana's Sunshine Healthcare for Rs.38 Cr to expand presence in West Africa, and 30% in India's Neuome Technologies for Rs.3.5 Cr to gain access to innovative bio-banking solutions.
Jul 24 2026 13:51:16
Dr. Lal PathLabs Ltd - 539524 - Grant Of Stock Options
Dr. Lal Path Labs Board of Directors met on July 24, 2026, approving the unaudited financial results for Q1 FY27. The Board also declared an interim dividend of Rs. 5 per equity share for FY 2026-27, with July 30, 2026, set as the record date.
Jul 24 2026 13:49:15
Dr. Lal PathLabs Ltd - 539524 - The Record Date For The Purpose Of Payment Of Interim Dividend Shall Be July 30, 2026
Dr. Lal Path Labs announced an interim dividend of ₹5 per equity share for FY2026-27. The record date for this dividend is fixed as July 30, 2026, with payment expected within 30 days of declaration.
Jul 24 2026 13:47:07
Dr. Lal PathLabs Ltd - 539524 - Board Meeting Outcome for Outcome Of Board Meeting - July 24, 2026
Dr. Lal Path Labs reported Q1 FY27 consolidated revenue of ₹797.7 crore and net profit of ₹170.5 crore. The company also declared an interim dividend of ₹5 per equity share with July 30, 2026 as the record date. Additionally, it approved the acquisition of 80% stake in Sunshine Healthcare Ltd, Ghana for ₹38 crore and 30% stake in Neuome Technologies Pvt Ltd, India for ₹3.5 crore.
Jul 24 2026 13:42:34
Dr. Lal PathLabs Ltd - 539524 - Received An Appellate Order From Income Tax Department
Dr. Lal Path Labs received a favorable appellate order from the Income Tax Department on July 17, 2026. The order allowed the company's appeal and confirmed a deduction of Rs.326.62 crore for ESOP expenses, positively impacting its financial position.
Jul 17 2026 19:40:32
Dr. Lal PathLabs Ltd - 539524 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Dr. Lal Path Labs has scheduled an earnings conference call for investors and analysts on July 24, 2026, at 5:30 PM IST. The call will cover the company's financial and operating performance for Q1 FY27, with a Q&A session for participants.
Jul 17 2026 13:25:36
Dr. Lal PathLabs Ltd - 539524 - Update on board meeting
Dr. Lal Path Labs Board will convene on July 24, 2026, to approve the un-audited Q1 FY27 financial results and consider an interim dividend for the financial year 2026-27.
Jul 17 2026 13:19:45
Dr. Lal PathLabs Ltd - 539524 - Corporate Action-Board to consider Dividend
Dr. Lal Path Labs board will consider an interim dividend for FY 2026-27 at the upcoming meeting. The decision will be made on July 24, 2026, for equity shareholders.
Jul 17 2026 13:15:17
Read More